Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Summary

The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.

Timeline

Start

2003-04-08

Primary completion

2018-12-11

Completion

2018-12-14

Drugs

Indications